Combining synergistic immune checkpoint inhibition with oncolytic virotherapy, the FilC/PD-1 recombinant vaccinia virus significantly increases anti-tumor immunity and slows the growth of HCC. This evidence concerns the gene PDCD1 and neoplasm.